{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:41:19Z","timestamp":1783698079178,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>Mucopolysaccharidosis type I (MPS I) is an inherited metabolic disorder caused by deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). The two current treatments [hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT)], are insufficiently effective in addressing neurologic disease, in part due to the inability of lysosomal enzyme to cross the blood brain barrier. With a goal to more effectively treat neurologic disease, we have investigated the effectiveness of AAV-mediated IDUA gene delivery to the brain using several different routes of administration. Animals were treated by either direct intracerebroventricular (ICV) injection, by intrathecal (IT) infusion into the cerebrospinal fluid, or by intranasal (IN) instillation of AAV9-IDUA vector. AAV9-IDUA was administered to IDUA-deficient mice that were either immunosuppressed with cyclophosphamide (CP), or immunotolerized at birth by weekly injections of human iduronidase. In animals treated by ICV or IT administration, levels of IDUA enzyme ranged from 3- to 1000-fold that of wild type levels in all parts of the microdissected brain. In animals administered vector intranasally, enzyme levels were 100-fold that of wild type in the olfactory bulb, but enzyme expression was close to wild type levels in other parts of the brain. Glycosaminoglycan levels were reduced to normal in ICV and IT treated mice, and in IN treated mice they were normalized in the olfactory bulb, or reduced in other parts of the brain. Immunohistochemical analysis showed extensive IDUA expression in all parts of the brain of ICV treated mice, while IT treated animals showed transduction that was primarily restricted to the hind brain with some sporadic labeling seen in the mid- and fore brain. At 6 months of age, animals were tested for spatial navigation, memory, and neurocognitive function in the Barnes maze; all treated animals were indistinguishable from normal heterozygous control animals, while untreated IDUA deficient animals exhibited significant learning and spatial navigation deficits. We conclude that IT and IN routes are acceptable and alternate routes of administration, respectively, of AAV vector delivery to the brain with effective IDUA expression, while all three routes of administration prevent the emergence of neurocognitive deficiency in a mouse MPS I model.<\/jats:p>","DOI":"10.3389\/fnmol.2021.618360","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:41:23Z","timestamp":1620628883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I"],"prefix":"10.3389","volume":"14","author":[{"given":"Lalitha R.","family":"Belur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junggu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Podetz-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhong","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen S.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Vulchanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley F.","family":"Kitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Fairbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F.","family":"Kozarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"William H.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter C.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"McIvor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/jgm.1028","article-title":"Prolonged expression of a lysosomal enzyme in mouse liver after sleeping beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses.","volume":"9","author":"Aronovich","year":"2007","journal-title":"J. Gene Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/mt.2009.87","article-title":"Systemic correction of storage disease in MPS I NOD\/SCID mice using the sleeping beauty transposon system.","volume":"17","author":"Aronovich","year":"2009","journal-title":"Mol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier.","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B5","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ymgme.2020.12.025","article-title":"Comparative systemic and neurologic effectiveness of intravenous and intrathecal AAV9 delivered individually or combined in a murine model of mucopolysaccharidosis type I.","volume":"132","author":"Belur","year":"2021","journal-title":"Mol. Gen. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.ymgmr.2020.100604","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes 9 and rh10.","volume":"24","author":"Belur","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I.","volume":"28","author":"Belur","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/hum.2008.155","article-title":"Human \u03b1- iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and bio-distribution.","volume":"20","author":"Ciron","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ana.20150","article-title":"Prevention of neuropathology in the mouse model of Hurler syndrome.","volume":"56","author":"Desmaris","year":"2004","journal-title":"Ann. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes.","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/s0169-409x(03)00101-7","article-title":"Spinal delivery of analgesics in experimental models of pain and analgesia.","volume":"55","author":"Fairbanks","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts.","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.brainresbull.2007.07.018","article-title":"Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.","volume":"74","author":"Garcia-Rivera","year":"2007","journal-title":"Brain Res. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ymgme.2008.07.003","article-title":"Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.","volume":"95","author":"Herati","year":"","journal-title":"Mol. Genet. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/jgm.1229","article-title":"Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.","volume":"10","author":"Herati","year":"","journal-title":"J. Gene Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.expneurol.2003.11.005","article-title":"Hematopoietic origin of microglial and perivascular cells in brain.","volume":"186","author":"Hess","year":"2004","journal-title":"Exp. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.","volume":"22","author":"Hinderer","year":"","journal-title":"Mol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"14894","DOI":"10.1073\/pnas.1413645111","article-title":"Liver- directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.","volume":"111","author":"Hinderer","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mt.2015.99","article-title":"Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates.","volume":"23","author":"Hinderer","year":"2015","journal-title":"Mol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and sustained expression of human iduronidase after intrathecal administration of adeno-associated virus serotype 9 in infant rhesus monkeys.","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques.","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: a new technique.","volume":"67","author":"Hylden","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1227\/NEU.0000000000000157","article-title":"Comparison of endovascular and intraventricular gene therapy with adeno-associated virus-\u03b1-L-iduronidase for Hurler disease.","volume":"74","author":"Janson","year":"2014","journal-title":"Neurosurgery"},{"key":"B27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00281-004-0166-2","article-title":"Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases.","volume":"26","author":"Krivit","year":"2004","journal-title":"Springer Semin. Immunopathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/mt.2009.236","article-title":"A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.","volume":"18","author":"Metcalf","year":"2010","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses.","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jpeds.2007.04.054","article-title":"Hematopoietic cell therapy for metabolic disease.","volume":"151","author":"Orchard","year":"2007","journal-title":"J. Pediatrics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine Hurler Syndrome.","volume":"27","author":"Ou","year":"2019","journal-title":"Mol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ymgme.2013.09.008","article-title":"High-dose enzyme replacement therapy in murine Hurler syndrome.","volume":"111","author":"Ou","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymthe.2006.03.015","article-title":"Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.","volume":"14","author":"Ponder","year":"2006","journal-title":"Mol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Treatment of lysosomal storage disorders: progress with enzyme replacement therapy.","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.trsl.2016.05.002","article-title":"Deleterious effects of interruption followed by reintroduction of enzyme replacement therapy on a lysosomal storage disorder.","volume":"176","author":"Schneider","year":"2016","journal-title":"Trans. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical testing of the safety and tolerability of lentiviral vector-mediated above-normal alpha-L-iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution good laboratory practice studies.","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.gt.3302735","article-title":"Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.","volume":"13","author":"Watson","year":"2006","journal-title":"Gene Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","article-title":"Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.","volume":"106","author":"Wolf","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","article-title":"Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.","volume":"43","author":"Wolf","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B41","first-page":"102","article-title":"Mucopolysaccharidosis type I.","volume":"12","author":"Wraith","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system.","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2021.618360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:41:29Z","timestamp":1620628889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2021.618360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":42,"alternative-id":["10.3389\/fnmol.2021.618360"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2021.618360","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"article-number":"618360"}}